Shareholder Update 13-05-2015

Shareholder Update 13-05-2015

Tissue Therapies (ASX.TIS) provides an update on the status of the European Medicines Agency’s (EMA) response to the company’s request for advice through the Scientific Advice Working Party (SAWP) process.

 

Shareholder Update 13-05-2015

About VitroGro® ECM Animation 04-05-2015

About VitroGro® ECM Animation 04-05-2015

The Tissue Therapies website now features an animation detailing how VitroGro® ECM works to restore healing in chronic wounds.

Shareholder Update 23-04-2015

Shareholder Update 23-04-2015

Tissue Therapies (ASX.TIS) provides an update to shareholders regarding its recent Oral Explanation with the European Medicines Authority’s Committee for Medical Products for Human Use (CHMP) held on 25 March 2015 in London.

Shareholder Update 23-04-2015

Shareholder Questions and Answers 23-04-2015

Shareholder Questions and Answers 23-04-2015

This Question and Answers document provides detailed technical information on the product, the recent EMA oral explanation and the EU regulatory process to date. Please also refer to the Shareholder Updated dated 23 April 2015.

Shareholder Questions and Answers 23-04-2015

Publications Update 17-04-2015

Publications Update 17-04-2015

Tissue Therapies Limited and its research partners are preparing several peer reviewed publications. These papers include further characterisation of the mode of actions of the VitroGro® protein and a methodology paper for the health economic model.

We are also reporting a well-conducted cross-trial comparison between patients treated with VitroGro® ECM and a large UK population treated with standard would care. Patients were matched for major prognostic factors, and this analysis showed significantly faster healing in the VitroGro® ECM group and a similar spectrum of adverse events was observed between groups.

Tissue Therapies Limited is a biomedical technology company that is developing significantly more effective treatments for acute and chronic wound healing applications, including chronic skin ulcers and burns. Tissue Therapies Limited is commercialising VitroGro® ECM, a technology created by cell biology, tissue engineering and protein engineering experts at the Institute of Health and Biomedical Innovation at the Queensland University of Technology. The company also has a licence for commercialisation of various patent families related to wound healing and other therapeutic uses. Tissue Therapies Limited's shares are traded on the Australian, Berlin and Frankfurt stock exchanges.

News

Shareholder Update 13-05-2015

Tissue Therapies (ASX.TIS) provides an update on the status of the European Medicines Agency’s (EMA) response to the company’s request for advice through the Scientific Advice Working Party (SAWP) process.

 

... More

About VitroGro® ECM Animation 04-05-2015

The Tissue Therapies website now features an animation detailing how VitroGro® ECM works to restore healing in chronic wounds.
... More

Shareholder Update 23-04-2015

Tissue Therapies (ASX.TIS) provides an update to shareholders regarding its recent Oral Explanation with the European Medicines Authority’s Committee for Medical Products for Human Use (CHMP) held on 25 March 2015 in London.

... More

Shareholder Questions and Answers 23-04-2015

This Question and Answers document provides detailed technical information on the product, the recent EMA oral explanation and the EU regulatory process to date. Please also refer to the Shareholder Updated dated 23 April 2015.

... More

Publications Update 17-04-2015

Tissue Therapies Limited and its research partners are preparing several peer reviewed publications. These papers include further characterisation of the mode of actions of the VitroGro® protein and a methodology paper for the health economic model.

We are also reporting a well-conducted cross-trial... More

Tissue Therapies Limited has identified that there is a significant need in wound care for improving the outcome of hard to heal wounds. Hard to heal wounds are defined as wounds that have not respond to standard therapy in an orderly and timely manner [1]. This type of delayed healing occurs in a variety of wound types (venous leg ulcers, arterial leg ulcers, mixed leg ulcers, diabetic foot ulcers and pressure ulcers) [1,2,3].

Treatment of hard to heal wounds is demanding on both patients and healthcare providers, with significant financial impact on the healthcare systems and the patients quality of life. For example, conservative costs to the UK National Health Service (NHS) are estimated at £2-3 billion per year. In the United States hard to heal wounds effect 6.5 million patients and is estimated to cost in excess of US$25 billion annually [4].

In Germany, according to cautious estimates, approximately 3-4 million people suffer from hard to heal wounds and costs associated are high for the Statutory Health Insurance (SHI) funds, the economy and patients [5]. The average annual cost to the SHI per patient for the treatment of venous leg ulcers alone was estimated at €7630.70 and the annual cost to the patient was estimated at €1027 [5].

About VitroGro® ECM animation

About VitroGro® ECM animation

 

Asx share price Berlin share price Frankfurt share price

In 2007, a UK hospital audit found that the drivers behind such high costs were[6];

  1. The relatively high incidence of non-healing wounds (1 in 4 wounds had been non-healing for at least six months);
  2. The prevalence of infections associated with non-healing wounds, resulting in longer hospital related care;
  3. Nursing time, which was associated 33-41% of the total cost of care and the cost of wound dressings, which were associated with 17-22% of the total cost of care.
Clearly there is an opportunity to provide a technological solution that reduces the time and resources taken to resolve hard to heal wounds, in addition to providing improved patient outcomes.

VitroGro® ECM is a new treatment for hard to heal wounds that is used in conjunction with standard care including moist wound dressing and compression. We see opportunities to have significant impact in wound care markets in Asia, Australia, Canada, Europe, New Zealand, the United States and other markets experiencing the economic burden of wound care. [learn more]


[1] Vowden P. Hard to heal wounds made easy. Wounds International 2011
[2] Srinivasaiah N. et al. A point prevalence survey of wounds in the North East of England. J. Wound Care 2007
[3] Vowden KR. and Vowden P. The prevalence, management, equipment provision and outcomes for patients with pressure ulceration identified in a wound care survey with one English health care district. J. Tissue Viability 2009.
[4] Harding K and Queen D. Chronic wounds and their management and prevention is a significant public health issue. Int. Wound J. 2010
[5] Purwins S et al. Cost of illness of chronic leg ulcers in Germany Int. Wound J. 2010
[6] Drew P et al. The cost of wound care for a local population in England. Int. Wound J. 2007